A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia

Trial Profile

A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs SEP 363856 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 13 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top